This applies to both T2D agents (metformin, sulfonylureas, SGLT2 inhibitors, GLP-1 receptor agonists, and, in some cases, basal insulin) and to insulin delivery strategies in T1D. Here, SLC5A2 is linked to type 2 diabetes mellitus.